Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
Phase 2
Completed
- Conditions
- Breast Neoplasms
- Registration Number
- NCT00174343
- Lead Sponsor
- Pfizer
- Brief Summary
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 46
Inclusion Criteria
- Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive
Exclusion Criteria
- Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
- Secondary Outcome Measures
Name Time Method To evaluate breast conservative surgery rate; To evaluate intratumoral anti-aromatase activity.
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇫🇷St. Cloud, France